Sydney Lupkin
Sydney Lupkin is the pharmaceuticals correspondent for NPR.
She was most recently a correspondent at Kaiser Health News, where she covered drug prices and specialized in data reporting for its enterprise team. She's reported on how tainted drugs can reach consumers, how companies take advantage of rare disease drug rules and how FDA-approved generics often don't make it to market. She's also tracked pharmaceutical dollars to patient advocacy groups and members of Congress. Her work has won the National Press Club's Joan M. Friedenberg Online Journalism Award, the National Institute for Health Care Management's Digital Media Award and a health reporting award from the Society for Advancing Business Editing and Writing.
Lupkin graduated from Boston University. She's also worked for ABC News, VICE News, MedPage Today and The Bay Citizen. Her internship and part-time work includes stints at ProPublica, The Boston Globe, The Boston Herald, The New England Center for Investigative Reporting and WCVB.
- World Health Organization declares Ebola outbreak in Congo a global health emergency
- FDA Commissioner Marty Makary resigns after tumultuous tenure
- FDA commissioner resigns after tumultuous tenure
- How a pill approved 25 years ago transformed cancer treatment
- Restrictions on obesity drug coverage force patients to pivot
- Spotty insurance coverage for GLP-1 drugs gets worse
- The FDA approves a new obesity pill, giving patients another option
- How to navigate the maze of drug discounts to get the best price